^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CXCR3 overexpression

    i
    Other names: C-X-C Motif Chemokine Receptor 3, G Protein-Coupled Receptor 9, CKR-L2, Interferon-Inducible Protein 10 Receptor, Chemokine (C-X-C Motif) Receptor 3, C-X-C Chemokine Receptor Type 3, IP-10 Receptor, CMKAR3, IP10-R, CD183, GPR9, MigR, Chemokine Receptor 3, CD183 Antigen, Mig Receptor, CXC-R3, CXCR-3, CD182, Mig-R, CXCR3
    Entrez ID:
    2833
    almost3years
    Immune determinants of CAR-T expansion in solid tumor patients receiving GD2 CAR-T cell therapy (AACR 2023)
    CXCR3 has been extensively studied on T cells, but its function on myeloid populations is yet to be fully explored. These results are the first to demonstrate that the peripheral immune environment prior to CAR-T administration may effectively predict and modulate CAR-T expansion in patients.
    Clinical • CAR T-Cell Therapy • IO biomarker
    |
    CXCR3 (C-X-C Motif Chemokine Receptor 3)
    |
    CXCR3 overexpression
    |
    GD2-CART
    3years
    IL-2/GM-CSF enhances CXCR3 expression in CAR-T cells via the PI3K/AKT and ERK1/2 pathways. (PubMed, J Cancer Res Clin Oncol)
    A multi-factorial amplification protocol can effectively improve CXCR3 expression on the surface of activated CAR-T cells in vitro, as well as enhance the chemotaxis ability of CAR-T cells in vivo, which significantly inhibit the growth of liver cancer.
    Journal • CAR T-Cell Therapy • IO biomarker
    |
    IL2 (Interleukin 2) • CD28 (CD28 Molecule) • CSF2 (Colony stimulating factor 2) • CXCR3 (C-X-C Motif Chemokine Receptor 3)
    |
    CSF2 expression • CXCR3 overexpression • IL2 expression
    over3years
    CXCR3 isoform A promotes head and neck cancer progression by enhancing stem-like property and chemoresistance. (PubMed, J Oral Pathol Med)
    This study first provides a novel insight of CXCR3 isoform A in HNC cancer progression via regulating cancer stem-like properties and chemoresistance, suggesting that CXCR3A may be a prognostic marker and novel target for HNC therapy.
    Journal
    |
    SOX2 • CXCR3 (C-X-C Motif Chemokine Receptor 3)
    |
    CXCR3 overexpression • SOX2 expression